Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 161-189

  Halilbasic, Emina ^a   Baghdasaryan, Anna ^a,b   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bile acids; Cholestasis; Cholestatic liver disease; Nuclear receptors

Indexed keywords

16ALPHA CYANOPREGNENOLONE; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BEZAFIBRATE; BUDESONIDE; CELL NUCLEUS RECEPTOR; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CLOTRIMAZOLE; DEXAMETHASONE; FARNESOID X RECEPTOR; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 19; GLUCOCORTICOID RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LITHOCHOLIC ACID; MULTIDRUG RESISTANCE PROTEIN 2; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOBARBITAL; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; RIFAMPICIN; SCOPARONE; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; CARCINOGENESIS; CHOLELITHIASIS; CHOLESTASIS; COLITIS; COMPETITIVE INHIBITION; DISEASE COURSE; DOWN REGULATION; DRUG TARGETING; FIBROGENESIS; GALLSTONE; GALLSTONE FORMATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GLUCONEOGENESIS; HUMAN; HYPERICUM PERFORATUM; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; INTRAHEPATIC CHOLESTASIS; INVERTED REPEAT; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; MONOTHERAPY; NEWBORN JAUNDICE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TOTAL PARENTERAL NUTRITION; TRANSACTIVATION; UPREGULATION; WOUND HEALING;

ANIMALS; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HOMEOSTASIS; HUMANS; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; URSODEOXYCHOLIC ACID;

EID: 84875599882     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.12.001     Document Type: Review

References (245)

1. Erlinger S. What is cholestasis in 1985?. J Hepatol 1985, 1:687-693.
2. Trauner M., Meier P.J., Boyer J.L. Molecular pathogenesis of cholestasis. N Engl J Med 1998, 339:1217-1227.
3. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology 2011, 53:1023-1034.
4. Trauner M., Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011, 140:1120-1125.e1-12.
5. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344.
6. Perissi V., Rosenfeld M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005, 6:542-554.
7. Makishima M., Okamoto A.Y., Repa J.J., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
8. Staudinger J.L., Goodwin B., Jones S.A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001, 98:3369-3374.
9. Xie W., Radominska-Pandya A., Shi Y., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 2001, 98:3375-3380.
10. Makishima M., Lu T.T., Xie W., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
11. Parks D.J., Blanchard S.G., Bledsoe R.K., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
12. Wang H., Chen J., Hollister K., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999, 3:543-553.
13. Forman B.M., Goode E., Chen J., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
14. Lu T.T., Repa J.J., Mangelsdorf D.J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 2001, 276:37735-37738.
15. Zhang Y., Kast-Woelbern H.R., Edwards P.A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003, 278:104-110.
16. Seol W., Choi H.S., Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995, 9:72-85.
17. Laffitte B.A., Kast H.R., Nguyen C.M., et al. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000, 275:10638-10647.
18. Huber R.M., Murphy K., Miao B., et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290:35-43.
19. Downes M., Verdecia M.A., Roecker A.J., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003, 11:1079-1092.
20. Anisfeld A.M., Kast-Woelbern H.R., Meyer M.E., et al. Syndecan-1 expression is regulated in an isoform specific manner by the farnesoid-X receptor. J Biol Chem 2003, 26:26.
21. Denson L.A., Sturm E., Echevarria W., et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121:140-147.
22. Ananthanarayanan M., Balasubramanian N., Makishima M., et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276:28857-28865.
23. Gerloff T., Geier A., Roots I., et al. Functional analysis of the rat bile salt export pump gene promoter. Eur J Biochem 2002, 269:3495-3503.
24. Plass J.R., Mol O., Heegsma J., et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 2002, 35:589-596.
25. Eloranta J.J., Kullak-Ublick G.A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 2005, 433:397-412.
26. Gupta S., Pandak W.M., Hylemon P.B. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 2002, 293:338-343.
27. Brendel C., Schoonjans K., Botrugno O.A., et al. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol 2002, 16:2065-2076.
28. Kir S., Zhang Y., Gerard R.D., et al. Nuclear receptors HNF4-alpha and LRH-1 cooperate in regulating Cyp7a1 in Vivo. J Biol Chem 2012, 287(49):41334-41341.
29. Abrahamsson A., Gustafsson U., Ellis E., et al. Feedback regulation of bile acid synthesis in human liver: importance of HNF-4alpha for regulation of CYP7A1. Biochem Biophys Res Commun 2005, 330:395-399.
30. Holt J.A., Luo G., Billin A.N., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003, 17:1581-1591.
31. Inagaki T., Choi M., Moschetta A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2:217-225.
32. Kim I., Ahn S.H., Inagaki T., et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007, 48:2664-2672.
33. Choi M., Moschetta A., Bookout A.L., et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006, 12:1253-1255.
34. Kir S., Beddow S.A., Samuel V.T., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331:1621-1624.
35. Tomlinson E., Fu L., John L., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
36. Fu L., John L.M., Adams S.H., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
37. Schaap F.G., van der Gaag N.A., Gouma D.J., et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49:1228-1235.
38. Zweers S.J., Booij K.A., Komuta M., et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012, 55:575-583.
39. Xu Y., Watanabe T., Tanigawa T., et al. Bile acids induce cdx2 expression through the farnesoid x receptor in gastric epithelial cells. J Clin Biochem Nutr 2010, 46:81-86.
40. Dawson P.A., Hubbert M., Haywood J., et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005, 280:6960-6968.
41. Boyer J.L., Trauner M., Mennone A., et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006, 290:G1124-G1130.
42. Zollner G., Marschall H.U., Wagner M., et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006, 3:231-251.
43. Huang L., Zhao A., Lew J.L., et al. Farnesoid X-receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003, 278:51085-51090.
44. Kast H.R., Goodwin B., Tarr P.T., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002, 277:2908-2915.
45. Deng R., Yang D., Yang J., et al. Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor. J Pharmacol Exp Ther 2006, 317:317-325.
46. Wang S., Lai K., Moy F.J., et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology 2006, 147:4025-4033.
47. Carter B.A., Prendergast D.R., Taylor O.A., et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007, 62(3):301-306.
48. Van Mil S.W., Milona A., Dixon P.H., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007, 133:507-516.
49. Alvarez L., Jara P., Sanchez-Sabate E., et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 2004, 13:2451-2460.
50. Chen F., Ananthanarayanan M., Emre S., et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004, 126:756-764.
51. Pauli-Magnus C., Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44:778-787.
52. Marzolini C., Tirona R.G., Gervasini G., et al. A common polymorphism in the bile acid receptor farnesoid x receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 2007, 21:1769-1780.
53. Ismair M.G., Stieger B., Cattori V., et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001, 121:1185-1190.
54. Kullak-Ublick G.A., Ismair M.G., Stieger B., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001, 120:525-533.
55. Moschetta A., Bookout A.L., Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 2004, 10:1352-1358.
56. Kovacs P., Kress R., Rocha J., et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 2008, 48(1):116-124.
57. Bertolotti M., Gabbi C., Anzivino C., et al. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur J Clin Invest 2006, 36:170-175.
58. Kanaya E., Shiraki T., Jingami H. The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner. Biochem J 2004, 382:913-921.
59. Zhang Y., Castellani L.W., Sinal C.J., et al. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004, 18:157-169.
60. Zollner G., Fickert P., Silbert D., et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003, 38:717-727.
61. Zollner G., Wagner M., Moustafa T., et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006, 290:G923-G932.
62. Donner M.G., Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001, 34:351-359.
63. Shoda J., Kano M., Oda K., et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 2001, 96:3368-3378.
64. Ogawa K., Suzuki H., Hirohashi T., et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000, 278:G438-G446.
65. Keitel V., Burdelski M., Warskulat U., et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41:1160-1172.
66. Zollner G., Wagner M., Fickert P., et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007, 27:920-929.
67. Kim I., Morimura K., Shah Y., et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
68. Yang F., Huang X., Yi T., et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007, 67:863-867.
69. Zhang Y., Xu P., Park K., et al. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 2008, 48:289-298.
70. He N., Park K., Zhang Y., et al. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 2008, 134:793-802.
71. Knisely A.S., Strautnieks S.S., Meier Y., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006, 44:478-486.
72. Zhang Y., Soto J., Park K., et al. Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. Mol Cell Biol 2010, 30:1341-1356.
73. Chen W.D., Wang Y.D., Zhang L., et al. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 2010, 51:953-962.
74. De Gottardi A., Touri F., Maurer C.A., et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004, 49:982-989.
75. Journe F., Durbecq V., Chaboteaux C., et al. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat 2009, 115:523-535.
76. Liu Y., Binz J., Numerick M.J., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003, 112:1678-1687.
77. Fiorucci S., Clerici C., Antonelli E., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005, 313:604-612.
78. Baghdasaryan A., Claudel T., Gumhold J., et al. Dual FXR/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO3- output. Hepatology 2011, 54(4):1303-1312.
79. McMurtrie H.L., Cleary H.J., Alvarez B.V., et al. The bicarbonate transport metabolon. J Enzyme Inhib Med Chem 2004, 19:231-236.
80. Chignard N., Mergey M., Barbu V., et al. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 2005, 42:549-557.
81. Cho W.K., Boyer J.L. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology 1999, 117:420-428.
82. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136:1435-1443.
83. Wang Y.D., Chen W.D., Wang M., et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643.
84. Li Y.T., Swales K.E., Thomas G.J., et al. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 2007, 27:2606-2611.
85. Xu Z., Huang G., Gong W., et al. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal 2012, 24:1658-1664.
86. Gadaleta R.M., van Erpecum K.J., Oldenburg B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472.
87. Ding J.W., Andersson R., Soltesz V., et al. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res 1993, 25:11-19.
88. Lorenzo-Zuniga V., Bartoli R., Planas R., et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003, 37:551-557.
89. Cahill C.J. Prevention of postoperative renal failure in patients with obstructive jaundice-the role of bile salts. Br J Surg 1983, 70:590-595.
90. Inagaki T., Moschetta A., Lee Y.K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103:3920-3925.
91. Modica S., Petruzzelli M., Bellafante E., et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012, 142(2):355-365.e1-4.
92. Fiorucci S., Antonelli E., Rizzo G., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
93. Fiorucci S., Rizzo G., Antonelli E., et al. A FXR-SHP regulatory cascade modulates TIMP-1 and MMPs expression in HSCs and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005, 314(2):584-595.
94. Fickert P., Fuchsbichler A., Wagner M., et al. The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. Hepatology 2009, 50:893-899.
95. Mason A., Luketic V., Lindor K., et al. Farnesoid-X Receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010, 52:357A.
96. Hirschfield G., Mason A., Gordon S., et al. A long term safty extenion trial of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) and UDCA in pimary biliary cirrhosis (PBC). Hepatology 2011, 54:429A.
97. Kowdley K.V., Jones D., Luketic V., The OCA PBC Study Group, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2012, 54:S13.
98. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002, 23:687-702.
99. Blumberg B., Sabbagh W., Juguilon H., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998, 12:3195-3205.
100. Kliewer S.A., Moore J.T., Wade L., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92:73-82.
101. Lehmann J.M., McKee D.D., Watson M.A., et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998, 102:1016-1023.
102. Moore L.B., Parks D.J., Jones S.A., et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000, 275:15122-15127.
103. Wentworth J.M., Agostini M., Love J., et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000, 166:R11-R16.
104. Huang W., Zhang J., Chua S.S., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 2003, 100:4156-4161.
105. Wada T., Gao J., Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab 2009, 20:273-279.
106. Xie W., Barwick J.L., Simon C.M., et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000, 14:3014-3023.
107. Jung D., Mangelsdorf D.J., Meyer U.A. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 2006, 281:19081-19091.
108. Castano G., Burgueno A., Fernandez Gianotti T., et al. The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther 2010, 31:583-592.
109. Owen B.M., Van Mil S.W., Boudjelal M., et al. Sequencing and functional assessment of hPXR (NR1I2) variants in intrahepatic cholestasis of pregnancy. Xenobiotica 2008, 38:1289-1297.
110. Karlsen T.H., Lie B.A., Frey Froslie K., et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006, 131:781-787.
111. Chai J., He Y., Cai S.Y., et al. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 2012, 55:1485-1494.
112. Chai J., Luo D., Wu X., et al. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg 2011, 15:996-1004.
113. Chen H.L., Liu Y.J., Wu S.H., et al. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008, 63:667-673.
114. Hanada K., Nakai K., Tanaka H., et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012, 27:301-306.
115. Bachs L., Pares A., Elena M., et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989, 1:574-576.
116. Cancado E.L., Leitao R.M., Carrilho F.J., et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 1998, 93:1510-1517.
117. Yerushalmi B., Sokol R.J., Narkewicz M.R., et al. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29:442-447.
118. Marschall H.U., Wagner M., Zollner G., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005, 129:476-485.
119. Kremer A.E., Martens J.J., Kulik W., et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010, 139:1008-1018.
120. Kremer A.E., van Dijk R., Leckie P., et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012, 56:1391-1400.
121. Stiehl A., Thaler M.M., Admirand W.H. The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis. N Engl J Med 1972, 286:858-861.
122. Bloomer J.R., Boyer J.L. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975, 82:310-317.
123. Huang W., Zhang J., Moore D.D. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004, 113:137-143.
124. Chen C., Staudinger J.L., Klaassen C.D. Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab Dispos 2003, 31:908-915.
125. Teng S., Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 2007, 151:367-376.
126. Beilke L.D., Aleksunes L., Holland R., et al. Car-mediated changes in bile acid composition contributes to hepatoprotection from lca-induced liver injury in mice. Drug Metab Dispos 2009, 37(5):1035-1045.
127. Wagner M., Halilbasic E., Marschall H.U., et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005, 42:420-430.
128. Renga B., Migliorati M., Mencarelli A., et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 2011, 1809:157-165.
129. Haughton E.L., Tucker S.J., Marek C.J., et al. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 2006, 131:194-209.
130. Marek C.J., Tucker S.J., Konstantinou D.K., et al. Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J 2005, 387:601-608.
131. Wallace K., Cowie D.E., Konstantinou D.K., et al. The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol 2010, 120:137-148.
132. Zhou C., Tabb M.M., Nelson E.L., et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006, 116:2280-2289.
133. Paunescu E. In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature 1970, 228:1188-1190.
134. Hu G., Xu C., Staudinger J.L. Pregnane X receptor is SUMOylated to repress the inflammatory response. J Pharmacol Exp Ther 2010, 335:342-350.
135. Dai G., He L., Bu P., et al. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 2008, 47:1277-1287.
136. Columbano A., Ledda-Columbano G.M., Pibiri M., et al. Gadd45beta is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia. Hepatology 2005, 42:1118-1126.
137. Huang W., Zhang J., Washington M., et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 2005, 19:1646-1653.
138. Yamamoto Y., Moore R., Goldsworthy T.L., et al. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004, 64:7197-7200.
139. Campbell M.J., Adorini L. The vitamin D receptor as a therapeutic target. Expert Opin Ther Targets 2006, 10:735-748.
140. Gascon-Barre M., Demers C., Mirshahi A., et al. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003, 37:1034-1042.
141. Abramovitch S., Dahan-Bachar L., Sharvit E., et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011, 60(12):1728-1737.
142. Chen X., Chen F., Liu S., et al. Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha, 25-dihydroxyvitamin D3 via the vitamin D receptor. Mol Pharmacol 2006, 69:1913-1923.
143. McCarthy T.C., Li X., Sinal C.J. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 2005, 280:23232-23242.
144. Echchgadda I., Song C.S., Roy A.K., et al. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol 2004, 65:720-729.
145. Chatterjee B., Echchgadda I., Song C.S. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol 2005, 400:165-191.
146. Honjo Y., Sasaki S., Kobayashi Y., et al. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J Endocrinol 2006, 188:635-643.
147. Vogel A., Strassburg C.P., Manns M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002, 35:126-131.
148. Tanaka A., Nezu S., Uegaki S., et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009, 50:1202-1209.
149. Fan L., Tu X., Zhu Y., et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005, 20:249-255.
150. Halmos B., Szalay F., Cserniczky T., et al. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci 2000, 45:1091-1095.
151. Kempinska-Podhorecka A., Wunsch E., Jarowicz T., et al. Vitamin D receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. Gastroenterol Res Pract 2012, 2012:408723.
152. Wikstrom Shemer E., Marschall H.U. Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2010, 89:1420-1423.
153. Barchetta I., Carotti S., Labbadia G., et al. Liver VDR, CYP2R1 and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with NASH or HCV hepatitis. Hepatology 2012, 56(6):2180-2187.
154. Spina C.S., Ton L., Yao M., et al. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 2007, 103:757-762.
155. de Lyra E.C., da Silva I.A., Katayama M.L., et al. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol 2006, 100:184-192.
156. Li Q., Gao Y., Jia Z., et al. Dysregulated Kruppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 2012, 143:799-810.e1-2.
157. Ruiz-Gaspa S., Guanabens N., Enjuanes A., et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010, 40:25-34.
158. Al-Harthy N., Kumagi T., Coltescu C., et al. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology 2010, 52:562-570.
159. Ogura M., Nishida S., Ishizawa M., et al. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J Pharmacol Exp Ther 2009, 328:564-570.
160. Chawla A., Repa J.J., Evans R.M., et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
161. Krey G., Braissant O., L'Horset F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
162. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94.
163. Bookout A.L., Jeong Y., Downes M., et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
164. Braissant O., Foufelle F., Scotto C., et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
165. Kliewer S.A., Xu H.E., Lambert M.H., et al. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001, 56:239-263.
166. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
167. Fang H.L., Strom S.C., Cai H., et al. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol Pharmacol 2005, 67:1257-1267.
168. Barbier O., Duran-Sandoval D., Pineda-Torra I., et al. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 2003, 278:32852-32860.
169. Jung D., Fried M., Kullak-Ublick G.A. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem 2002, 277:30559-30566.
170. Barbier O., Trottier J., Kaeding J., et al. Lipid-activated transcription factors control bile acid glucuronidation. Mol Cell Biochem 2009, 326(1-2):3-8.
171. Marrapodi M., Chiang J.Y. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res 2000, 41:514-520.
172. Patel D.D., Knight B.L., Soutar A.K., et al. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem J 2000, 351(Pt 3):747-753.
173. Post S.M., Duez H., Gervois P.P., et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001, 21:1840-1845.
174. Roglans N., Vazquez-Carrera M., Alegret M., et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol 2004, 59:855-861.
175. Ghonem N., Ananthanarayanan M., Soroka C.J., et al. Fenofibrate, a specific peroxisome proliferator-activated receptor alpha (PPARα) agonist, up-regulates MDR3/ABCB4 expression in human hepatocytes. Hepatology 2012, 56(S1):541A.
176. Ghose R., Mulder J., von Furstenberg R.J., et al. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J Hepatol 2007, 46:115-123.
177. Harada K., Nakanuma Y. Biliary innate immunity: function and modulation. Mediators Inflamm 2010, 2010.
178. Zhang F., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-gamma cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012, 24:596-605.
179. Harada K., Isse K., Kamihira T., et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 2005, 41:1329-1338.
180. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000, 275:35715-35722.
181. Matsumoto T., Miyazaki H., Nakahashi Y., et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004, 30:125-136.
182. Shoda J., Inada Y., Tsuji A., et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res 2004, 45:1813-1825.
183. Nakamuta M., Fujino T., Yada R., et al. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010, 48:22-28.
184. Honda A., Ikegami T., Nakamuta M., et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2012, [Epub ahead of print].
185. Ohmoto K., Mitsui Y., Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 2001, 21:223-224.
186. Yano K., Kato H., Morita S., et al. Is bezafibrate histologically effective for primary biliary cirrhosis?. Am J Gastroenterol 2002, 97:1075-1077.
187. Kanda T., Yokosuka O., Imazeki F., et al. Bezafibrate treatment: a new medical approach for PBC patients?. J Gastroenterol 2003, 38:573-578.
188. Kurihara T., Maeda A., Shigemoto M., et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002, 97:212-214.
189. Kurihara T., Niimi A., Maeda A., et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000, 95:2990-2992.
190. Nakai S., Masaki T., Kurokohchi K., et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000, 95:326-327.
191. Han X.F., Wang Q.X., Liu Y., et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 2012, 13:219-224.
192. Liberopoulos E.N., Florentin M., Elisaf M.S., et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010, 4:120-126.
193. Levy C., Peter J.A., Nelson D.R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011, 33:235-242.
194. Dohmen K., Mizuta T., Nakamuta M., et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004, 10:894-898.
195. Itakura J., Izumi N., Nishimura Y., et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004, 29:216-222.
196. Miyaguchi S., Ebinuma H., Imaeda H., et al. A novel treatment for refractory primary biliary cirrhosis?. Hepatogastroenterology 2000, 47:1518-1521.
197. Hazzan R., Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010, 44:371-373.
198. Iwasaki S., Akisawa N., Saibara T., et al. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 2007, 37(Suppl 3):S515-S517.
199. Takeuchi Y., Ikeda F., Fujioka S., et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol 2011, 26:1395-1401.
200. Akbar S.M., Furukawa S., Nakanishi S., et al. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 2005, 40:157-163.
201. Caroli-Bosc F.X., Le Gall P., Pugliese P., et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001, 46:540-544.
202. Hidaka M., Iwasaki S., Matsui T., et al. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010, 45(5):912-918.
203. Landrier J.F., Thomas C., Grober J., et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 2004, 279:45512-45518.
204. Carrella M., Feldman D., Cogoi S., et al. Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat. Hepatology 1999, 29:1825-1832.
205. Hooiveld G.J., Vos T.A., Scheffer G.L., et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 1999, 117:678-687.
206. Kurihara T., Akimoto M., Abe K., et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993, 15:890-898.
207. Kamisako T., Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 1995, 90:1187-1188.
208. Ritzel U., Leonhardt U., Nather M., et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002, 36:454-458.
209. Stojakovic T., Putz-Bankuti C., Fauler G., et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007, 46:776-784.
210. Marra F., DeFranco R., Robino G., et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol 2005, 11:4931-4938.
211. Snow K.L., Moseley R.H. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci 2007, 80:732-740.
212. Funk C., Ponelle C., Scheuermann G., et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001, 59:627-635.
213. Baghdasaryan A., Claudel T., Kosters A., et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010, 59:521-530.
214. Rivera-Espinoza Y., Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int 2009, 29:1457-1466.
215. Rose A.J., Vegiopoulos A., Herzig S. Role of glucocorticoids and the glucocorticoid receptor in metabolism: insights from genetic manipulations. J Steroid Biochem Mol Biol 2010, 122:10-20.
216. Jung D., Fantin A.C., Scheurer U., et al. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004, 53:78-84.
217. Eloranta J.J., Jung D., Kullak-Ublick G.A. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006, 20:65-79.
218. Khan A.A., Chow E.C., Porte R.J., et al. Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos 2009, 30:241-258.
219. Pascussi J.M., Gerbal-Chaloin S., Fabre J.M., et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000, 58:1441-1450.
220. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003, 1619:243-253.
221. Lu Y., Zhang Z., Xiong X., et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid x receptor. Gastroenterology 2012, 143:1630-1640.e8.
222. Gossard A.A., Lindor K.D. Autoimmune hepatitis: a review. J Gastroenterol 2012, 47:498-503.
223. Poupon R. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis 2011, 29:85-88.
224. Alvaro D., Gigliozzi A., Marucci L., et al. Corticosteroids modulate the secretory processes of the rat intrahepatic biliary epithelium. Gastroenterology 2002, 122:1058-1069.
225. Arenas F., Hervias I., Uriz M., et al. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008, 118:695-709.
226. Prieto J., Qian C., Garcia N., et al. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993, 105:572-578.
227. Medina J.F. Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis. Dig Dis 2011, 29:103-112.
228. Tanaka H., Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 1992, 188:942-948.
229. Miura T., Ouchida R., Yoshikawa N., et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001, 276:47371-47378.
230. Tanaka H., Makino Y., Miura T., et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996, 156:1601-1608.
231. Mitchison H.C., Bassendine M.F., Malcolm A.J., et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989, 10:420-429.
232. Yamanishi Y., Nosaka Y., Kawasaki H., et al. Sterol and bile acid metabolism after short-term prednisolone treatment in patients with chronic active hepatitis. Gastroenterol Jpn 1985, 20:246-251.
233. Volzke H., Baumeister S.E., Alte D., et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion 2005, 71:97-105.
234. Leuschner M., Maier K.P., Schlichting J., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999, 117:918-925.
235. Rautiainen H., Karkkainen P., Karvonen A.L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005, 41:747-752.
236. Angulo P., Jorgensen R.A., Keach J.C., et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 31:318-323.
237. Hempfling W., Grunhage F., Dilger K., et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003, 38:196-202.
238. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36(Suppl 1):S3-S12.
239. Sato H., Macchiarulo A., Thomas C., et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 2008, 51(6):1831-1841.
240. Verma A., Maxwell J.D., Ang L., et al. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis. Osteoporos Int 2002, 13:677-682.
241. Fickert P., Wagner M., Marschall H.U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
242. Halilbasic E., Fiorotto R., Fickert P., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009, 49:1972-1981.
243. Moustafa T., Fickert P., Magnes C., et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012, 142:140-151.e12.
244. Yoon Y.B., Hagey L.R., Hofmann A.F., et al. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986, 90:837-852.
245. Trauner M., Claudel T., Fickert P., et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010, 28:220-224.